Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 3, 2010, Pages 299-308

  Barrett, John A ^a   Joyal, John L ^a   Hillier, Shawn M ^a   Maresca, Kevin P ^a   Femia, Frank J ^a   Kronauge, James F ^a   Boyd, Marie ^b   Mairs, Robert J ^b   Babich, John W ^a  

^a A Subsidiary of Lantheus Holdings   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

123 131I MIBG; neuroblastoma; neuroendocrine; radiotherapeutic; tissue distribution; Ultratrace

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; TRACER;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTERIAL PRESSURE; ARTICLE; COMPARATIVE STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RETENTION; DRUG UPTAKE; ELECTROCARDIOGRAPHY; EXPERIMENTAL DOG; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRESSURE TRANSDUCER; PRIORITY JOURNAL; RAT; TELEMETRY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

3-IODOBENZYLGUANIDINE; ANIMAL STRUCTURES; ANIMALS; BLOOD PRESSURE; BONE MARROW; BRADYCARDIA; DOGS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART RATE; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; MICE; MICE, NUDE; MYOCARDIUM; NEUROBLASTOMA; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954910396     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0695     Document Type: Article

References (18)

1. Williams LE, DeNardo GL, Meredith RF. Targeted radionuclide therapy. Med Phys 2008;35:3062.
2. Wieland DM, Wu J, Brown LE, et al. Radiolabeled adren- ergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21:349.
3. Jacques S, Tobes MC, Sisson JC, et al. Mechanism of uptake of norepinephrine and meta-iodobenzylguanidine into cultured human pheochromocytoma cells. J Nucl Med 1984;25:122.
4. Anton M, Wagner B, Haubner R, et al. Use of norepineph- rine transporter as a reporter for non invasive imaging of genetically modified cells. J Gene Med 2004;6:119.
5. Vaidyanathan G, Zalutsky MR. 1-(m-[211At]astatobenzyl)gua- nidine: Synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjug Chem 1992;3:499.
6. Rutgers M, Gubbels AAT, Hoefnagel CA, et al. A human neuroblastoma xenograft model 131I-MIBG biodistribution and targeted radiotherapy. In: Evans AE, D'Angio GJ, Knudson AG, et al.,eds., Advances in Neuroblastoma Research. New York: Wiley-Liss, 1991:471-478.
7. Hunter DH, Zhu X. Preparation of radiolabeled haloaro- matics polymer-based intermediates. WO Patent 99/18053, US Patent 6,461,585 (1999).
8. Verberne HJ, Bruin K, Habraken JBA, et al. No carrier added versus carrier added 123I-metaiodobenzylguanidine for assessment of cardiac sympathetic nerve activity. Eur J Nucl Med 2006;33:483.
9. Gaze MN, Chang YC, Flux GD, et al. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195.
10. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054.
11. Brans B, Bodei L, Giammarile F, et al. Clinical radionuclide therapy dosimetry: The quest for the holy gray. Eur J Nucl Med Mol Imaging 2007;34:772.
12. Portess DI, Bauer G, Hill MA, et al. Low-dose irradiation of nontransformed cells stimulates the selective removal of precancerous cells via intercellular induction of apoptosis. Cancer Res 2007;67:1246.
13. Marengo B, Raffaghello L, Pistoia V, et al. Reactive oxygen species: Biological stimuli of neuroblastoma cell response. Cancer Lett 2005;228:111.
14. Grune T, Davies KJ. Breakdown of oxidized proteins as a part of secondary antioxidant defenses in mammalian cells. Biofactors 1997;6:165.
15. Kolby L, Bernhardt P, Levin-Jakobsen AM, et al. Uptake of metaiodobenzylguanidine in neuroendocrine tumors is mediated by vesicular monoamine transporters. Br J Cancer 2003;89:1383.
16. Mairs RJ, Russell J, Cunningham S, et al. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer 1995; 31:576.
17. Boyd M, Ross S, Owens J, et al. Preclinical evaluation of no carrier added 131I-metabenzylguanidine for the treatment of tumors transfected with noradrenaline transporter gene. Lett Drug Des Discov 2004;1:1.
18. Mairs RJ, Cunningham SH, Russell J, et al. No-carrier-added 131I-mIBG: Evaluation of a novel preparation of a therapeutic radiopharmaceutical. J Nucl Med 1995;36:1088.